Last Update 08 Mar 26

Fair value Increased 4.31%

RVTY: 2026 Tools Demand And China Recovery Will Support Higher Earnings Power

Revvity's analyst price target edges higher from $114.63 to $119.56 as analysts factor in updated assumptions around discount rates, modestly slower revenue growth and slightly lower profit margins, along with a higher future P/E multiple supported by a series of recent target raises from Baird, TD Cowen, Evercore ISI, Barclays and Jefferies.

Analyst Commentary

Bullish analysts have been lifting their price targets in a fairly tight range, which points to a shared view that Revvity's risk or return profile has shifted enough to justify higher valuation assumptions, even as they factor in tempered expectations for revenue growth and margins.

Bullish Takeaways

Bullish analysts are leaning on recovering end markets and early signs of improvement in China as support for higher target prices, which feeds into a more constructive stance on medium term revenue potential.
Survey work pointing to healthy procedure and CapEx trends into 2026 is being used to support the case that Revvity can execute on demand for tools and related offerings, which underpins confidence in the earnings power that can justify richer P/E multiples.
The series of price target increases in quick succession signals growing comfort with the company's positioning within MedTech tools, which some bullish analysts frame as a set up for the stock to participate if the group remains in favor with investors.
By assigning higher future P/E multiples, bullish analysts are effectively giving more credit to management's ability to deliver on its plan despite slower modeled revenue growth and slightly lower margins.

Bearish Takeaways

Even within favorable survey data, analysts flag that sector rotation and policy risks tied to ACA and Medicare changes are issues that, in their view, require a discount to the most optimistic valuation outcomes.
The need to model modestly slower revenue growth and slightly lower profit margins shows that analysts are not treating the recovery in end markets as a straight line, which can cap how far target multiples extend.
Some analysts highlight that recovering demand and early China recovery signs are still developing, so execution against these factors is key before investors may be willing to support meaningfully higher P/E levels.
References to bears watching healthcare policy and reimbursement trends suggest that a portion of the Street still sees a risk that external factors could pressure volumes or pricing, which feeds into more conservative target assumptions for some models.

What's in the News

Revvity launched multiple new discovery platforms at SLAS2026, including the Opera Phenix OptIQ high content screening system, the EnVision Nexus One multimode plate reader, and the AssayMate liquid handling workstation. These platforms are aimed at supporting high throughput drug discovery workflows and integrated lab automation (Key Developments).
The company introduced its upcoming Signals Xynthetica Models as a Service AI offering within the Revvity Signals platform. It is designed to support AI augmented molecular and materials design by linking in silico generation, predictive modeling, and experimental validation in one governed environment (Key Developments).
Revvity announced a collaboration with Eli Lilly to make Lilly TuneLab predictive models available through the Revvity Signals platform. The collaboration uses a federated learning approach so participating organizations can apply Lilly's AI and ML models to their own discovery programs while keeping proprietary data private (Key Developments).
Management issued revenue guidance for fiscal 2026, forecasting total revenue of US$2.96b to US$2.99b and organic revenue growth of 2% to 3% for the year ending January 3, 2027 (Key Developments).
The company also provided guidance for the fourth quarter and full year 2025, with expected Q4 2025 revenue of about US$772 million and full year 2025 revenue of about US$2.855b, alongside reported and organic growth figures for both periods (Key Developments).

Valuation Changes

Fair Value: revised slightly higher from $114.63 to $119.56.
Discount Rate: nudged higher from 8.41% to 8.53%, implying a slightly higher assumed risk level for future cash flows.
Revenue Growth: trimmed from 5.49% to 5.14%, signaling more conservative top line expectations.
Net Profit Margin: eased from 20.04% to 19.67%, reflecting slightly lower modeled profitability.
Future P/E: raised from 21.0x to 22.2x, indicating a higher valuation multiple applied to forward earnings.

0 views

Key Takeaways

Expansion in high-growth software and diagnostics, alongside product mix shift, is driving recurring, higher-margin revenue and robust earnings growth.
Strategic investments, contract wins, and aggressive share buybacks are supporting revenue momentum, operational flexibility, and enhanced capital returns.
Regulatory shifts, weak end-market demand, margin pressures, trade risks, and limited growth investments threaten Revvity's long-term profitability and competitive strength.

Catalysts

About Revvity

Provides health sciences solutions, technologies, and services worldwide.What are the underlying business or industry changes driving this perspective?

Accelerating adoption of Revvity's high-growth software solutions (30%+ organic growth in Signals, record orders, high ARR and net retention), driven by pharma/biotech spending on digital transformation, supports sustained revenue growth and recurring, higher-margin streams.
Secular demand for advanced diagnostics, driven by aging populations and expansion of personalized medicine, is reflected in robust growth for reproductive health and newborn screening businesses (high single-digit global growth), positioning these segments to drive topline revenue and earnings expansion.
Ongoing shift in product mix toward higher-margin, software-enabled and consumables-driven offerings (e.g., SaaS Signals, reagents, new IDS i20 platform), along with structural cost actions, are expected to materially expand operating and net margins, with 2026 set to start at a higher 28% operating margin baseline.
Strategic investments and contract wins (e.g., Genomics England sequencing ramp–$10M visibility and pipeline for further assays/new products) leverage global R&D funding growth and genomics advances, expanding the customer pool and supporting revenue acceleration.
Aggressive share repurchase activity (nearly $450M in H1 2025, ~6% share count reduction over 12 months) enhances EPS growth and capital return, while operational flexibility and prudent cash deployment bolster future earnings and margin resilience.

Revvity Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Revvity's revenue will grow by 5.4% annually over the next 3 years.
Analysts assume that profit margins will increase from 10.0% today to 18.3% in 3 years time.
Analysts expect earnings to reach $599.9 million (and earnings per share of $5.47) by about September 2028, up from $278.7 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $356 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 24.4x on those 2028 earnings, down from 35.4x today. This future PE is lower than the current PE for the US Life Sciences industry at 29.3x.
Analysts expect the number of shares outstanding to decline by 4.63% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.88%, as per the Simply Wall St company report.

Revvity Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Accelerating regulatory and reimbursement changes in China, such as the DRG debundling policy, are causing high-margin multiplex diagnostics test volumes to decline and could further erode revenue and operating margins, especially given China represents a meaningful market segment for Revvity's Diagnostics business.
Persistent weakness in academic and government end-markets due to funding pressures (e.g., uncertainties around NIH budgets and public sector spend) is limiting organic growth and exposing Revvity to ongoing revenue volatility and dampened long-term topline outlook.
Global cost-containment policies in healthcare (e.g., DRG, Sunshine Act, VBP in China), alongside increased focus on reducing diagnostic spending, may lead to sustained pricing and volume pressures, especially in legacy multiplex and certain diagnostics segments, negatively impacting recurring revenue streams and net margins.
Intensifying tariff risks and evolving cross-border trade dynamics between the US, EU, and China create recurring operational complexity and cost pressures that may require restructuring of Revvity's supply chain and manufacturing footprint, posing threats to gross margins and increasing execution risk.
The company's reliance on structural cost actions, share buybacks, and the absence of compelling acquisition targets may provide short-term EPS support, but could limit strategic investment in growth initiatives and innovation, ultimately constraining long-term earnings expansion and competitive positioning against larger, better-capitalized peers.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $116.812 for Revvity based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $162.0, and the most bearish reporting a price target of just $100.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $3.3 billion, earnings will come to $599.9 million, and it would be trading on a PE ratio of 24.4x, assuming you use a discount rate of 7.9%.
Given the current share price of $85.04, the analyst price target of $116.81 is 27.2% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Revvity?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

RVTY: Operating Margins And Buyback Plan Will Drive Share Recovery Ahead